News

Immatics believes that ACT approaches to be developed by the new company can achieve a step change in the treatment of cancer, by delivering significant, long-lasting clinical benefits.

The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen’s University in Kingston, Ontario . "Non-small cell lung cancer continues to

The AMBITION study was a randomised, double-blind Phase 3b/4 study designed to compare the efficacy and safety of ambrisentan in combination with tadalafil to monotherapy in treatment-naïve patients

Pursuant to the study agreement, UMass Medical School will provide Enumeral with tissue samples and blood samples from subjects with melanoma who are being treated with Ipilimumab (Yervoy).

The product, which is based on Corium’s proprietary transdermal formulation and adhesive technology, is designed to deliver donepezil (the active ingredient in Aricept) for up to seven days

Afatinib has also been granted orphan drug designation by the FDA – a status given to a product intended for the treatment of a rare disease or condition.

As previously announced, the investigational drug was granted FDA Fast Track designation for the treatment of recurrent high-grade glioma, which includes glioblastoma and anaplastic astrocytoma, and is poised

Respreeza, a highly purified Alpha-1 protein derived from human plasma, is the only Alpha-1 proteinase inhibitor that has been proven in a prospective double blind, placebo controlled trial

TAPROS is the Prostaglandin F2a Analogue co-developed by Santen and Asahi Glass Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo) for the reduction of intraocular pressure (IOP) in glaucoma and ocular